-+ 0.00%
-+ 0.00%
-+ 0.00%

FAETH THERAPEUTICS - REPORTS 12% HYPERGLYCEMIA, 21% STOMATITIS, 5% DISCONTINUATION RATE IN PHASE 2 TRIAL

Reuters·11/09/2026 12:00:03

Please log in to view news